Showing results (91-100 of 636) with videos related to
Sort By:
Pageof 64
Proceedings of the National Academy of Sciences of the United States of America|August 25, 2025
Loss of ICOSL expression in the progression to cervical carcinomaGerard J Nuovo, Esmerina Tili, Carlo M CroceBiochimica Et Biophysica Acta|May 25, 2010
Interplay between microRNAs and the epigenetic machinery: an intricate networkMarilena V Iorio, Claudia Piovan, Carlo M CroceAnnual Review of Pathology|October 2, 2013
MicroRNAs in cancerGianpiero Di Leva, Michela Garofalo, Carlo M CroceCurrent Pharmaceutical Design|February 1, 2014
MicroRNAs as anti-cancer therapyMichela Garofalo, Gianpiero Di Leva, Carlo M CroceInternational Reviews of Immunology|October 9, 2009
miR-155: on the crosstalk between inflammation and cancerEsmerina Tili, Carlo M Croce, Jean-Jacques MichailleBest Practice & Research. Clinical Haematology|August 21, 2007
The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemiaGeorge A Calin, Yuri Pekarsky, Carlo M CroceCancer Journal (Sudbury, Mass.)|February 28, 2008
MicroRNAsMuller Fabbri, Carlo M Croce, George A CalinLeukemia & Lymphoma|January 23, 2009
MicroRNAs in the ontogeny of leukemias and lymphomasMuller Fabbri, Carlo M Croce, George A CalinUpsala Journal of Medical Sciences|February 22, 2012
MicroRNA in cancer: new hopes for antineoplastic chemotherapyGianpiero Di Leva, Daniel Briskin, Carlo M CrocePharmacological Reviews|November 25, 2025
miR-155 aberrant expression impairs tumor rejection because of its targeting of ICOSL and multiple pathways implicated in the antitumor responseEsmerina Tili, Jean-Jacques Michaille, Carlo M CrocePageof 64